Abstract
BackgroundSynuclein gamma (SNCG) expression is associated with advanced disease and chemoresistance in multiple solid tumors. Our goal was to determine if SNCG protein expression in ovarian cancer was correlated with clinicopathologic variables and patient outcomes.MethodsTissue microarrays from primary tumors of 357 ovarian, fallopian tube, and primary peritoneal cancer patients, who underwent primary surgery at Roswell Park Cancer Institute between 1995 and 2007, were immunohistochemically stained for SNCG. A pathologist blinded to patient data scored tumors as positive if ≥10 % of the sample stained for SNCG. Medical records were reviewed for clinicopathologic and demographic variables. Between the positive and negative groups, Wilcoxon rank-sum test was used to compare the median ages and Fisher’s exact test was used to compare groups in categorical variables. Cox proportional hazard models examined associations between SNCG and overall and progression-free survival.ResultsThe median follow-up was 36 months, median overall survival was 39 months, and median progression-free survival was 18 months. SNCG presence was associated with clinical variables of serous histology, grade 3 disease, suboptimal debulking, ascites at surgery, FIGO stage III-IV cancer, or initial CA-125 level >485. There was no significant difference in overall survival (HR 1.06 95 % CI 0.81–1.39 P 0.69) or progression-free survival (HR 1.16 95 % CI 0.89–1.50 P 0.28) for patients with or without SNCG expression.ConclusionsSNCG expression in ovarian cancer is frequent in patients with high-risk features, but it does not correlate with chemotherapy response, overall survival, or progression-free survival.Electronic supplementary materialThe online version of this article (doi:10.1186/s13048-016-0281-4) contains supplementary material, which is available to authorized users.
Highlights
Synuclein gamma (SNCG) expression is associated with advanced disease and chemoresistance in multiple solid tumors
SNCG expression occurs with advanced disease and chemoresistance in many cancers, and in breast cancer, SNCG has been causatively linked to increased proliferation, metastasis, and drug resistance [12]
The hypothesis, namely that SNCG expression was associated with worse clinical outcomes, was refuted, as the results of our study found no association between SNCG expression and Overall survival (OS) or Progression-free survival (PFS) in primary tumors
Summary
Synuclein gamma (SNCG) expression is associated with advanced disease and chemoresistance in multiple solid tumors. High rates of recurrence and associated mortality, coupled with advancements in the characterization of intracellular signaling pathways in carcinogenesis, have prompted investigation into other potential targets that can be used in the treatment of ovarian cancer, such as intracellular signaling pathways [3]. Among such targets, synuclein gamma (SNCG) was proposed as a potential target in ovarian cancer therapy [4]. SNCG expression occurs with advanced disease and chemoresistance in many cancers, and in breast cancer, SNCG has been causatively linked to increased proliferation, metastasis, and drug resistance [12]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
